A.1.
Recommendation percentage | Allocated dose percentage | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
d1 | d2 | d3 | d4 | d5 | d6 | d1 | d2 | d3 | d4 | d5 | d6 | |
Scenario A | ||||||||||||
QLCRMW | 3.1 | 83.4 | 13.4 | 0.1 | 0.0 | 0.0 | 18.6 | 60.5 | 19.7 | 1.2 | 0.0 | 0.0 |
QLCRM | 3.4 | 85.9 | 10.7 | 0.0 | 0.0 | 0.0 | 19.4 | 62.6 | 17.4 | 0.6 | 0.0 | 0.0 |
Scenario B | ||||||||||||
QLCRMW | 0.0 | 9.9 | 85.5 | 4.6 | 0.0 | 0.0 | 9.0 | 18.6 | 58.6 | 13.0 | 0.7 | 0.0 |
QLCRM | 0.0 | 12.7 | 85.3 | 2.0 | 0.0 | 0.0 | 9.1 | 21.1 | 60.8 | 8.9 | 0.2 | 0.0 |
Scenario C | ||||||||||||
QLCRMW | 0.0 | 2.5 | 77.2 | 19.9 | 0.4 | 0.0 | 9.1 | 14.0 | 52.5 | 22.3 | 1.9 | 0.0 |
QLCRM | 0.0 | 3.0 | 83.8 | 13.3 | 0.0 | 0.0 | 9.2 | 14.9 | 57.0 | 18.3 | 0.7 | 0.0 |
Scenario D | ||||||||||||
QLCRMW | 0.0 | 0.0 | 65.0 | 33.7 | 1.2 | 0.0 | 8.3 | 8.5 | 38.4 | 38.5 | 6.1 | 0.1 |
QLCRM | 0.0 | 0.1 | 83.0 | 17.0 | 0.0 | 0.0 | 8.4 | 8.6 | 51.4 | 30.3 | 1.4 | 0.0 |
Scenario E | ||||||||||||
QLCRMW | 0.0 | 0.0 | 4.9 | 88.7 | 6.3 | 0.1 | 8.3 | 8.4 | 12.4 | 53.5 | 15.9 | 1.4 |
QLCRM | 0.0 | 0.0 | 8.8 | 90.5 | 0.6 | 0.0 | 8.4 | 8.4 | 15.0 | 60.4 | 7.8 | 0.1 |
Scenario F | ||||||||||||
QLCRMW | 0.0 | 0.0 | 1.8 | 67.9 | 28.7 | 1.6 | 8.4 | 8.5 | 11.9 | 43.7 | 24.2 | 3.4 |
QLCRM | 0.0 | 0.0 | 2.7 | 80.7 | 16.5 | 0.0 | 8.4 | 8.5 | 13.1 | 50.9 | 18.5 | 0.6 |
Scenario G | ||||||||||||
QLCRMW | 0.0 | 0.0 | 0.0 | 2.8 | 61.8 | 35.4 | 8.3 | 8.3 | 8.5 | 12.7 | 36.7 | 25.4 |
QLCRM | 0.0 | 0.0 | 0.0 | 2.6 | 79.6 | 17.8 | 8.4 | 8.3 | 8.4 | 12.3 | 45.0 | 17.6 |
Scenario H | ||||||||||||
QLCRMW | 0.0 | 0.0 | 0.0 | 6.0 | 73.2 | 20.8 | 8.3 | 8.4 | 8.9 | 18.6 | 41.6 | 14.1 |
QLCRM | 0.0 | 0.0 | 0.0 | 1.8 | 82.5 | 15.7 | 8.3 | 8.4 | 8.7 | 15.0 | 48.0 | 11.5 |
Results at the target dose are in bold.
QLCRMW, quasi-likelihood continual reassessment method using Wedderburn variance and its corresponding likelihood; QLCRM: quasi-likelihood continual reassessment method (our proposal, with the Bernoulli variance).